Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population

Inclusion Criteria: For HAE: patient with a documented diagnosis of HAE: * type I (from an antigenic deficiency of the C1 esterase inhibitor) or type II (from a functional deficiency of the C1 esterase inhibitor). The existence of a mutation in SERPING1 was not necessary for the inclusion * HAE with normal C1-INH (ex type III) with a required mutation in FXII gene or with a typical family history of HAE diagnosed by a specialized physician belonging to CREAK network. For AE resulting of mast cell activation: a documented diagnosis of AE resulting of mast cell activation included: * mastocytosis, * chronic spontaneous urticaria, * acute urticaria after exposure of allergen during allergy challenge tests, * mast cell activation syndrome. For the control group: * composed of patients who presented a stabilized disease (that was not infectious, not auto-inflammatory or inflammatory disease and without implication of endothelial cells). Exclusion Criteria: * Over 18 years or under 1 year. * Diagnosis of HAE with a normal C1 esterase inhibitor or AE of unknown aetiology. * Patients with HAE who received an acute attack treatment before the blood sample (the C1 esterase inhibitor concentrate or a bradykinin B2 receptor antagonist); patients with HAE who received a prophylactic treatment (danazol). * Patients who were treated by omalizumab or corticosteroid treatment.